Hareman Group   Report issue

For profit Phase 2
Founded: Winnipeg Canada (1970)

Organization Overview

First Clinical Trial
2019
NCT04121169
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

ImmuniMed Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

Chicken egg-derived anti-C.difficile polyclonal antibodies (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Clostridium Infections (Phase 2)

Communicable Diseases (Phase 2)

Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1